GlassScriptPhysician profile
Audrey C Ko
NPI 1891089546
$139,981.28
in general payments reported to CMS, 2019-2025
16 companies · $28K in 2025
The $28K reported for 2025 was more than what 96% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
See the full distribution for Ophthalmic Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,226 · 2020: $92.97 · 2021: $10K · 2022: $38K · 2023: $44K · 2024: $18K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $39K · Consulting Fee: $22K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Travel and Lodging: $5,132 · Food and Beverage: $3,638 · Education: $10.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $38,807.75 |
| Consulting Fee | $21,653.03 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,037.50 |
| Travel and Lodging | $5,131.79 |
| Food and Beverage | $3,638.01 |
| Education | $10.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $89,191.85 | 2020-2023 | Tepezza |
| Amgen INC. | $46,017.21 | 2024-2025 | Tepezza |
| US Retina LLC | $1,729.23 | 2021-2022 | |
| Biotissue Holdings INC. | $1,065.07 | 2023 | |
| Medtronic USA, INC. | $1,025.05 | 2019 | |
| Ani Pharmaceuticals, INC. | $197.80 | 2025 | Purified Cortrophin Gel |
| Allergan, INC. | $169.04 | 2019-2021 | |
| Sight Sciences, INC. | $137.62 | 2022 | |
| Aerie Pharmaceuticals, INC. | $121.74 | 2021 | |
| Novartis Pharmaceuticals Corporation | $117.15 | 2019 | |
| Galderma Laboratories, L.P. | $60.62 | 2021 | |
| Alcon Vision LLC | $54.03 | 2020-2024 | Clareon |
| Bausch & Lomb Americas INC. | $40.61 | 2022-2025 | Miebo, Xiidra |
| Merz Pharmaceuticals, LLC | $23.80 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $15.45 | 2024 | Xdemvy |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acera Surgical, INC. | $15.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$68,283.45 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audrey Ko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.